Tagomics

Welcome to the team, Stephen Evens! Stephen holds a Master’s Degree in Mathematics from the University of Reading and has over eight years of experience developing, managing, and assuring scientific software in regulated environments. For the past three years, Stephen has been working as a Staff Bioinformatics Engineer at Exact Sciences, where he helped develop the TAPS methylation technology and led the production pipeline development of the Oncodetect MRD test. We are delighted to welcome Stephen to the team. He will lead our bioinformatics engineering function, enhancing our computational infrastructure and advancing our software development.

Connect with our Chair, Dr. Kirk Malloy, and CEO, Dr. Jack Kennefick, at the American Society of Clinical Oncology Annual Meeting #ASCO24. Discover how #Tagomics' innovative multiomic platform can revolutionise your drug discovery and development pipelines. Reach out to schedule a meeting! #Biomarkers #DrugDevelopment #ClinicalTrials #Diagnostic #Multiomic #CancerResearch

We are delighted to join Nucleate and IQ Capital for an evening of game-changing insights and engaging networking.   Our CTO Debora Lucarelli will join a fantastic panel of speakers exploring the next-generation of sequencing technologies and applications. Together with Peter Crane and Alisandra Denton, the panel will delve into emerging trends, cutting-technologies and the latest scientific advances.    Our CEO Jack Kennefick is attending the networking session and is looking forward to connecting to the many tech focused entrepreneurs and investors attending.    🏁 Key Event Details 🏁 🗓 Tuesday, May 28th 🔗 RSVP Here - https://lu.ma/xfa8h525

Welcome to the team, Lylia Ouboussad! 🎉 Lylia holds a PhD in cancer genetics from Brunel University and has extensive experience as a postdoctoral research fellow at the University of Leeds. Her initial postdoctoral project focused on the epigenetics of myeloid differentiation within the experimental haematology section. Subsequently, she investigated the pathogenesis of rheumatoid arthritis, analysing treatment responses to biologics-based therapies by assessing the epigenetics/cell signalling pathway profiles of patients involved in clinical trials. After a decade in academia, Lylia transitioned to the cell and gene therapy sector. Initially, she contributed to Achilles Therapeutics as a Translational Senior Scientist, concentrating on characterising novel clonal neoantigen products. She then moved to Quell Therapeutics, a CAR T-regulatory T cells (T-regs) company, assuming the role of Senior Scientist. In this capacity, she led the immune monitoring team and oversaw translational operations. We're delighted to welcome Lylia as our Clinical Study Coordinator. Her role will involve designing and managing the clinical studies essential for the development of our products. #Welcome #Tagomics #Team

Want to learn more about Tagomics’ approach in uncovering disease-associated biomarkers via epigenomic profiling?   The latest Enseqlopedia blog post by James Hadfield features Tagomics recent pre-print on how ‘Active-Seq’, the company’s fast epigenetic profiling platform, can be utilised to achieve genome-wide profiling with low DNA input from cell lines, liquid biopsies and formalin-fixed paraffin embedded (FFPE) tissue.   Read more below👇

Welcome to the team Marianna Kyritsi! 🎉 Marianna holds a PhD in Protein Biochemistry from University of Athens and was a postdoctoral Research Associate at Imperial College London in the field of cell signalling and cancer biology. With a particular interest in biotechnology and genomic-based diagnostics, she then joined Illumina as an R&D scientist where she played a pivotal role in the development and technical validation of NIPT and Oncology NGS based assays and IVD end-to-end clinical genomic solutions. We’re delighted to have Marianna join our team. Her knowledge and experience will be crucial in our efforts to drive the clinical development and application of our innovative multiomics platform. #Tagomics #Team

Welcome to the team Valentina Miano! Valentina is a molecular biologist with more than ten years’ experience in the field of Epigenetics. During her PhD and first post-doc appointment at the University of Turin she led several projects on the epigenetic mechanisms regulating non-coding RNAs’ expression in breast cancer cells, as well as developing strategies to detect lncRNAs in liquid biopsies. As a Research Associate at the University of Cambridge she focused her studies on the role of different RNA modifying enzymes and RNA modifications in regulating cancer cells’ biology. She developed her research approach to biological problems by combining experimental and computational methods, especially by generating and analysing genomic and transcriptomic data. We're pleased that Valentina has joined the team! She will help shape our research efforts and expand the capabilities of our innovative multiomics platform. #Tagomics #TagTeam

Check out this excellent summary of our recent preprint by James Hadfield in his latest Enseqlopedia blog post! - https://lnkd.in/eyj2ztA3 You can access our preprint paper here: https://lnkd.in/eQpyYvUE

We are delighted to welcome Isobel Deamer to the team! Isobel holds a first-class Biological Sciences degree from Loughborough University with a year in industry working as an R&D Student Scientist at Abbott Diabetes Care. As part of the Test Method Development Team at Abbott, she gained experience in the development and validation of in-vitro diagnostics as well as writing and optimising SOPs. Her final year research project at University ‘The Development of High-throughput Protein and RNA Extraction Protocols From 3D Breast Cancer Spheroids’, involved ascertaining the optimum conditions for high-throughput analysis of breast cancer spheroids and how they may impact downstream applications. Isobel will play a key role in driving the clinical development of our platform. #Tagomics #TagTeam #Innovation

Our CEO, Dr Jack Kennefick, is in San Diego attending the American Association for Cancer Research #AACR Conference from the 5th-10th April! Connect with him to learn how Tagomics' multiomic biomarker discovery and diagnostic approach can propel your drug discovery efforts, enhance your clinical trials, and advance diagnostic development. #AACR2024 #Innovation #Healthcare #Tagomics